HighCom Limited (ASX:HCL)

CTI BioPharma Ratios and Metrics

Market cap in millions AUD. Fiscal year is July - June.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Market Capitalization	37	12	44	40	29	38
Market Cap Growth	-47.97%	-71.84%	10.10%	34.82%	-21.90%	116.33%
Enterprise Value	31	13	39	40	23	35
Last Close Price	0.36	0.12	0.43	0.40	0.41	0.70
PE Ratio	11.89	-	7.18	6.93	-	124.72
PS Ratio	0.66	0.27	0.49	0.68	1.04	0.88
PB Ratio	1.13	0.40	1.04	1.14	1.38	2.61
P/TBV Ratio	1.21	0.43	1.12	1.21	1.51	2.97
P/FCF Ratio	4.39	-	-	1.65	-	-
P/OCF Ratio	3.56	18.73	-	1.53	-	-
EV/Sales Ratio	0.54	0.30	0.43	0.70	0.81	0.83
EV/EBITDA Ratio	8.91	-	3.61	5.13	-	2208.38
EV/EBIT Ratio	13.48	-	4.17	5.87	-	-
EV/FCF Ratio	3.61	-	-	1.68	-	-
Debt / Equity Ratio	0.05	0.02	0.04	0.10	0.21	0.25
Debt / EBITDA Ratio	0.51	-	0.14	0.41	-	10.39
Debt / FCF Ratio	0.21	-	-	0.14	-	-
Asset Turnover	1.42	0.78	1.16	1.05	0.84	1.30
Inventory Turnover	2.22	1.66	2.66	2.26	2.04	6.32
Quick Ratio	1.47	1.13	1.06	1.13	1.06	0.98
Current Ratio	3.29	3.25	1.89	1.56	2.58	1.55
Return on Equity (ROE)	10.08%	-31.76%	15.84%	20.41%	-22.16%	2.73%
Return on Assets (ROA)	3.55%	-10.71%	7.49%	7.77%	-7.62%	-0.72%
Return on Capital (ROIC)	4.30%	-16.51%	14.14%	13.44%	-11.76%	-1.65%
Return on Capital Employed (ROCE)	6.60%	-	21.30%	18.50%	-	-
Earnings Yield	7.16%	-97.53%	13.93%	14.44%	-13.48%	0.80%
FCF Yield	22.79%	-3.73%	-63.91%	60.68%	-29.37%	-14.13%
Buyback Yield / Dilution	0.88%	-	-11.79%	-33.54%	-33.62%	-26.89%

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.